Effects of neobractatin and trametinib on gene expression in pancreatic cancer cells
Pancreatic ductal adenocarcinoma carcinoma (PDAC) is a highly lethal disease and ranks as the seventh leading cause of cancer-related deaths worldwide. Neobractatin (NBT), a natural compound derived from Garcinia bracteate, has shown great antitumor effects and has been identified as a regulator of pyroptosis in esophageal cancer cells. The effectiveness of combining NBT with the common targeted drug trametinib in inhibiting PDAC and its underlying mechanisms remain unclear. In this study, we aimed to explore the therapeutic potential of combining NBT with trametinib in PDAC. Overall design: To investigate the synergistic effects of NBT and trametinib in regulating anti-tumor effects, MIA PaCa-2 cells were treated with NBT (1 µM) or trametinib (5 µM) or in a combination for 12 h. We then performed gene expression profiling analysis using data obtained from RNA-seq of 4 different cells. Comparative gene expression profiling analysis of RNA-seg data for MIA PaCa-2 cells.